TACC3 is the most common fusion partner for FGFR3, but several novel fusion partners have been recently identified, including WHSC1 (also known as NSD2 or MMSET).29,30 FGFR3 fusions are more commonly found in urothelial carcinoma, glioblastoma, and nonsmall cell lung cancer and have not been reported in CRC so its clinical significance remains unknown.31 This evidence concerns the gene FGFR3 and urothelial carcinoma.